健康经济学评价中透明度、开放性与可重复性研究实践常被忽视
该研究评估了2019年MEDLINE收录的200项健康经济学评价,发现仅少数报告了研究方案(16%)、原始数据与分析代码(5%),56%的研究报告了重现基础病例增量成本效果比所需数据;使用指南者的数据报告率高于未使用者(66% vs 44%,风险比1.50,95%CI 1.15-1.97)。结论认为透明度、开放性与可重复性研究实践在健康经济学评价中常被忽视。
要点
- 56%的研究报告了重现基础病例增量成本效果比所需数据。
- 使用指南者的数据可重现率高于未使用者(66% vs 44%,风险比1.50,95%CI 1.15-1.97)。
- 仅5%的研究提及可获取原始数据和分析代码以供再分析。
核心结论
- 透明度、开放性和可重复性研究实践在健康经济学评价中常被忽视,本研究为该领域未来进展比较提供了基线数据。
研究设计与样本
- 研究设计为对2019年MEDLINE收录的健康经济学评价进行随机抽样评估,纳入以每生命年、质量调整生命年或伤残调整生命年成本报告增量成本效果比的英文文章,共纳入147种期刊的200项研究。
主要发现
- 93项(47%)研究以开放获取文章发表,150项(75%)研究为基于模型的经济学评价。
- 109项(55%)研究的作者自我报告使用了指南(如用于研究实施或报告)。
- 31项(16%)研究报告了依据研究方案开展工作。
- 112项(56%)研究报告了重现基础病例分析增量成本效果比所需的数据。
- 使用指南的研究报告数据可重现的比例高于未使用指南的研究(72/109 [66%] vs 40/91 [44%];风险比1.50,95%置信区间1.15-1.97)。
关键数值与推荐
- 使用指南的研究数据可重现率为66%(72/109),未使用指南的研究为44%(40/91),风险比1.50(95%置信区间1.15-1.97)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To investigate the extent to which articles of economic evaluations of healthcare interventions indexed in MEDLINE incorporate research practices that promote transparency, openness, and reproducibility. STUDY DESIGN AND SETTING: We evaluated a random sample of health economic evaluations indexed in MEDLINE during 2019. We included articles written in English reporting an incremental cost-effectiveness ratio in terms of costs per life years gained, quality-adjusted life years, and/or disability-adjusted life years. Reproducible research practices, openness, and transparency in each article were extracted in duplicate. We explored whether reproducible research practices were associated with self-report use of a guideline. RESULTS: We included 200 studies published in 147 journals. Almost half were published as open access articles (n = 93; 47%). Most studies (n = 150; 75%) were model-based economic evaluations. In 109 (55%) studies, authors self-reported use a guideline (e.g., for study conduct or reporting). Few studies (n = 31; 16%) reported working from a protocol. In 112 (56%) studies, authors reported the data needed to recreate the incremental cost-effectiveness ratio for the base case analysis. This percentage was higher in studies using a guideline than studies not using a guideline (72/109 [66%] with guideline vs. 40/91 [44%] without guideline; risk ratio 1.50, 95% confidence interval 1.15-1.97). Only 10 (5%) studies mentioned access to raw data and analytic code for reanalyses. CONCLUSION: Transparency, openness, and reproducible research practices are frequently underused in health economic evaluations. This study provides baseline data to compare future progress in the field.
引用
- Catalá-López F, Ridao M, Tejedor-Romero L, et al. Transparency, openness, and reproducible research practices are frequently underused in health economic evaluations. J Clin Epidemiol. 2023. PMID: 37939742. doi:10.1016/j.jclinepi.2023.10.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。